No More Excuses! Small Biotechs Report Growing Dissatisfaction With Their CROs

Small biotechs and pharma companies have gained an increased percentage of the clinical research market over the last decade. While some experts may consider this growth a flash in the pan, a recent study conducted by McKinsey indicates otherwise;

“While large pharma companies are expected to grow R&D spending at a rate of 4 percent annually—to $234 billion for the industry in 2025—R&D spending in biotech is forecasted to grow twice as fast, at up to 8 percent per year”

Some biotech companies  might be smaller than an established legacy brand, but that doesn’t mean they have to accept poor quality service or excuses from their CRO. 

As R&D spending by small biotechs continues to rise, CROs are struggling to meet the requirements, maintain quality, and provide these clients the attention they need and deserve.

In this research paper, we highlight three of the most common problems small biotechs and pharmas face when working with traditional CROs and recommend a solution designed to help maintain quality and meet timelines.